Tumor cells are heterogeneous populations and emerging evidence suggests that the capability of a tumor to grow and propagate is dependent on a small subset of cells within a tumor, termed cancer stem cells (CSCs). These cancer stem cells can both self-renew and produce differentiated progeny. Cancer stem cells have been shown to be resistant to chemotherapy and radiation. This may explain why conventional treatment results in tumor shrinkage, also why most tumors ultimately recur. The new therapeutic plan targeting cancer stem cells demonstrated promising results and it becomes a clear trend that cancer research will focus on cancer stem cell in the future.

Why us?
Our ultimate goal is to build a commercialized World-class cancer stem cell platform which has a R&D Center based both in US and in China, focusing on primary human pancreatic, breast, liver, gastric, colon, lung and head & neck cancers and aiming to facilitate the development of novel cancer therapeutics.

Our team has multiple years of experience in life science and pharmaceutical industry, particularly in the emerging cancer stem cell research field. Our service can provide you with customized research programs in the most effective and efficient manner possible.